
Marianne P. Allen
Examiner (ID: 17617, Phone: (571)272-0712 , Office: P/1647 )
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1818, 1812, 1645, 1805, 1631, 1647 |
| Total Applications | 2168 |
| Issued Applications | 1046 |
| Pending Applications | 251 |
| Abandoned Applications | 885 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18537483
[patent_doc_number] => 20230242576
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/990507
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990507
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990507 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18451559
[patent_doc_number] => 20230192837
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/054284
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -55
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054284
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054284 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES | Nov 9, 2022 | Pending |
Array
(
[id] => 18212462
[patent_doc_number] => 20230058726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => CHEMOPREVENTION USING CONTROLLED- RELEASE FORMULATIONS OF ANTI-INTERLEUKIN 6 AGENTS, SYNTHETIC VITAMIN A ANALOGUES OR METABOLITES, AND ESTRADIOL METABOLITES
[patent_app_type] => utility
[patent_app_number] => 17/977691
[patent_app_country] => US
[patent_app_date] => 2022-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17977691
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/977691 | CHEMOPREVENTION USING CONTROLLED- RELEASE FORMULATIONS OF ANTI-INTERLEUKIN 6 AGENTS, SYNTHETIC VITAMIN A ANALOGUES OR METABOLITES, AND ESTRADIOL METABOLITES | Oct 30, 2022 | Pending |
Array
(
[id] => 18657750
[patent_doc_number] => 20230303704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => FGFR3 ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/045995
[patent_app_country] => US
[patent_app_date] => 2022-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44228
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045995
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Oct 11, 2022 | Pending |
Array
(
[id] => 18310223
[patent_doc_number] => 20230114123
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 17/961502
[patent_app_country] => US
[patent_app_date] => 2022-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961502
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/961502 | METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS | Oct 5, 2022 | Abandoned |
Array
(
[id] => 20645821
[patent_doc_number] => 12600756
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-14
[patent_title] => Recombinant modified fibroblast growth factors and therapeutic uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/939238
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 13
[patent_no_of_words] => 30125
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939238
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/939238 | Recombinant modified fibroblast growth factors and therapeutic uses thereof | Sep 6, 2022 | Issued |
Array
(
[id] => 19816798
[patent_doc_number] => 20250075005
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-06
[patent_title] => USE OF ALPHA-ENOLASE ANTAGONIST IN TREATING OF FIBROTIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/292352
[patent_app_country] => US
[patent_app_date] => 2022-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5340
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18292352
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/292352 | USE OF ALPHA-ENOLASE ANTAGONIST IN TREATING OF FIBROTIC DISEASES | Aug 18, 2022 | Pending |
Array
(
[id] => 18257437
[patent_doc_number] => 20230084477
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/818798
[patent_app_country] => US
[patent_app_date] => 2022-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818798
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/818798 | COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | Aug 9, 2022 | Abandoned |
Array
(
[id] => 19989672
[patent_doc_number] => 20250127894
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-24
[patent_title] => PROCESS FOR PRODUCING ARMED IMMUNE CELLS
[patent_app_type] => utility
[patent_app_number] => 18/682632
[patent_app_country] => US
[patent_app_date] => 2022-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18183
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18682632
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/682632 | PROCESS FOR PRODUCING ARMED IMMUNE CELLS | Aug 9, 2022 | Pending |
Array
(
[id] => 18536100
[patent_doc_number] => 20230241187
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => Lysosomal Targeting Peptides and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/815468
[patent_app_country] => US
[patent_app_date] => 2022-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815468
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/815468 | Lysosomal Targeting Peptides and Uses Thereof | Jul 26, 2022 | Pending |
Array
(
[id] => 19800516
[patent_doc_number] => 20250066441
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/580810
[patent_app_country] => US
[patent_app_date] => 2022-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97868
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18580810
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Jul 17, 2022 | Pending |
Array
(
[id] => 19543153
[patent_doc_number] => 20240360189
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => DIMERIC PROTEIN COMPLEXES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/577400
[patent_app_country] => US
[patent_app_date] => 2022-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48231
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18577400
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/577400 | DIMERIC PROTEIN COMPLEXES AND USES THEREOF | Jul 10, 2022 | Pending |
Array
(
[id] => 19417423
[patent_doc_number] => 20240293546
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => D2C7 EGFR AND EGFR VIII BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND METHODS OF MAKING AND USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/574656
[patent_app_country] => US
[patent_app_date] => 2022-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10355
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18574656
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/574656 | D2C7 EGFR AND EGFR VIII BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND METHODS OF MAKING AND USING SAME | Jun 30, 2022 | Pending |
Array
(
[id] => 18420180
[patent_doc_number] => 20230174641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => ANTI-ACTH ANTIBODIES AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/850135
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 136003
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850135
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850135 | Anti-ACTH antibodies and use thereof | Jun 26, 2022 | Issued |
Array
(
[id] => 20158223
[patent_doc_number] => 12384835
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Cysteine linked nanobody dimers
[patent_app_type] => utility
[patent_app_number] => 17/850339
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 14
[patent_no_of_words] => 26808
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 205
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850339
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850339 | Cysteine linked nanobody dimers | Jun 26, 2022 | Issued |
Array
(
[id] => 18004984
[patent_doc_number] => 20220363750
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => ARTHRITIS TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/807939
[patent_app_country] => US
[patent_app_date] => 2022-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17807939
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/807939 | Arthritis treatment | Jun 20, 2022 | Issued |
Array
(
[id] => 18004977
[patent_doc_number] => 20220363743
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => ANTI-ANGPT2 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/842904
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24145
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842904
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/842904 | ANTI-ANGPT2 ANTIBODIES | Jun 16, 2022 | Abandoned |
Array
(
[id] => 18093173
[patent_doc_number] => 20220411514
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE
[patent_app_type] => utility
[patent_app_number] => 17/834703
[patent_app_country] => US
[patent_app_date] => 2022-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834703
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/834703 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | Jun 6, 2022 | Pending |
Array
(
[id] => 19855588
[patent_doc_number] => 12258411
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-25
[patent_title] => Anti-CCR8 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/831398
[patent_app_country] => US
[patent_app_date] => 2022-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 13
[patent_no_of_words] => 48637
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831398
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/831398 | Anti-CCR8 antibodies and uses thereof | Jun 1, 2022 | Issued |
Array
(
[id] => 17988897
[patent_doc_number] => 20220354934
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => Lysosomal Targeting Peptides and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/829620
[patent_app_country] => US
[patent_app_date] => 2022-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15486
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829620
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/829620 | Lysosomal Targeting Peptides and Uses Thereof | May 31, 2022 | Pending |